Ildong Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-03-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ildong.com
A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.
- Conditions
- Hypertension, Dyslipidemia
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 600
- Registration Number
- NCT03648801
A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo
- Conditions
- Chronic Hepatitis b
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 3000
- Registration Number
- NCT03642340
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
Phase 4
- Conditions
- Hepatitis B
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 76
- Registration Number
- NCT03604016
Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia
Phase 3
Completed
- Conditions
- Hypertension With Hyperlipidemia
- Interventions
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 134
- Registration Number
- NCT03566316
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 116
- Registration Number
- NCT03363269
- Locations
- 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Myongji Hospital, Goyang, Korea, Republic of
🇰🇷Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea, Republic of
Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: TWYNSTA(Telmisartan+Amlodipine besylate)Drug: TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 44
- Registration Number
- NCT03032315
- Locations
- 🇰🇷
Chonbuk National University Hospital, Chonbuk, Korea, Republic of
The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction
Phase 3
- Conditions
- Erectile DysfunctionBenign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 330
- Registration Number
- NCT02862483
- Locations
- 🇰🇷
Catholic university of korea, Seoul ST. Mary's Hospital., Seoul, Korea, Republic of
Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients.
Phase 3
- Conditions
- Functional Dyspepsia
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 354
- Registration Number
- NCT02831543
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seong Nam, Kyung-gi, Korea, Republic of
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia
Phase 3
- Conditions
- Benign Prostate Hyperplasia
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 588
- Registration Number
- NCT02827578
- Locations
- 🇰🇷
Samsung medical center, Seoul, Korea, Republic of
Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
Phase 3
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 146
- Registration Number
- NCT02792088
- Locations
- 🇰🇷
Severance Hospital of Yonsei University, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath